| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6790458 | HERON THERAPS INC | Pharmaceutical compositions using semi-solid delivery vehicle |
May, 2021
(2 years ago) | |
| US6613355 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions |
Jun, 2021
(2 years ago) | |
| US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(5 months from now) | |
| US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(5 months from now) | |
| US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(5 months from now) | |
| US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(5 months from now) | |
| US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(5 months from now) | |
Sustol is owned by Heron Theraps Inc.
Sustol contains Granisetron.
Sustol has a total of 7 drug patents out of which 2 drug patents have expired.
Expired drug patents of Sustol are:
- US6790458
- US6613355
Sustol was authorised for market use on 09 August, 2016.
Sustol is available in injection, extended release;subcutaneous dosage forms.
Sustol can be used as treatment or prevention of nausea and vomiting, prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy.
The generics of Sustol are possible to be released after 28 September, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 09, 2019 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE;SUBCUTANEOUS
SUSTOL family patents
